Mini-Review Article

Circulating MicroRNAs: Diagnostic Value as Biomarkers in the Detection of Non-alcoholic Fatty Liver Diseases and Hepatocellular Carcinoma

Author(s): Minakshi Rana, Manisha Saini, Rina Das*, Sumeet Gupta, Tanishq Joshi and Dinesh Kumar Mehta

Volume 12, Issue 2, 2023

Published on: 10 May, 2023

Page: [99 - 113] Pages: 15

DOI: 10.2174/2211536612666230330083146

Price: $65

Abstract

Non-alcoholic fatty liver disease (NAFLD), a metabolic-related disorder, is the most common cause of chronic liver disease which, if left untreated, can progress from simple steatosis to advanced fibrosis and eventually cirrhosis or hepatocellular carcinoma, which is the leading cause of hepatic damage globally. Currently available diagnostic modalities for NAFLD and hepatocellular carcinoma are mostly invasive and of limited precision. A liver biopsy is the most widely used diagnostic tool for hepatic disease. But due to its invasive procedure, it is not practicable for mass screening. Thus, noninvasive biomarkers are needed to diagnose NAFLD and HCC, monitor disease progression, and determine treatment response. Various studies indicated that serum miRNAs could serve as noninvasive biomarkers for both NAFLD and HCC diagnosis because of their association with different histological features of the disease. Although microRNAs are promising and clinically useful biomarkers for hepatic diseases, larger standardization procedures and studies are still required.

Keywords: Non-alcoholic fatty liver disease, hepatocellular carcinoma, microrna, noninvasive biomarker, fibrosis, cirrhosis, chronic hepatitis.

Graphical Abstract
[1]
Godoy-Matos AF, Silva Júnior WS, Valerio CM. NAFLD as a continuum: From obesity to metabolic syndrome and diabetes. Diabetol Metab Syndr 2020; 12(1): 60.
[http://dx.doi.org/10.1186/s13098-020-00570-y] [PMID: 32684985]
[2]
Gori M, Arciello M, Balsano C. MicroRNAs in nonalcoholic fatty liver disease: novel biomarkers and prognostic tools during the transition from steatosis to hepatocarcinoma. BioMed Res Int 2014; 2014: 1-14.
[http://dx.doi.org/10.1155/2014/741465] [PMID: 24745023]
[3]
Singh A, Ranjan V, Das R, Bhatti K, Mehta DK, Chidurala RM. Serum biomarkers for noninvasive diagnosis of liver diseases: How laudable are these tools? Curr Chem Biol 2021; 15(2): 128-38.
[http://dx.doi.org/10.2174/2212796814999201111204639]
[4]
Liu XL, Pan Q, Zhang RN, et al. Disease-specific miR-34a as diagnostic marker of non-alcoholic steatohepatitis in a Chinese population. World J Gastroenterol 2016; 22(44): 9844-52.
[http://dx.doi.org/10.3748/wjg.v22.i44.9844] [PMID: 27956809]
[5]
Zarrinpar A, Gupta S, Maurya MR, Subramaniam S, Loomba R. Serum microRNAs explain discordance of non-alcoholic fatty liver disease in monozygotic and dizygotic twins: A prospective study. Gut 2016; 65(9): 1546-54.
[http://dx.doi.org/10.1136/gutjnl-2015-309456] [PMID: 26002934]
[6]
Jiang L, Cheng Q, Zhang BH, Zhang MZ. Circulating microRNAs as biomarkers in hepatocellular carcinoma screening: A validation set from China. Medicine 2015; 94(10): e603.
[http://dx.doi.org/10.1097/MD.0000000000000603] [PMID: 25761179]
[7]
Yamamoto Y, Kondo S, Matsuzaki J, et al. Highly sensitive circulating MicroRNA panel for accurate detection of hepatocellular carcinoma in patients with liver disease. Hepatolcommun 2019; 4(2): 284-97.
[http://dx.doi.org/10.1002/hep4.1451]
[8]
Kim E, Viatour P. Hepatocellular carcinoma: Old friends and new tricks. Exp Mol Med 2020; 52(12): 1898-907.
[http://dx.doi.org/10.1038/s12276-020-00527-1] [PMID: 33268834]
[9]
Auguet T, Aragonès G, Berlanga A, et al. miR33a/miR33b and miR122 as possible contributors to hepatic lipid metabolism in obese women with nonalcoholic fatty liver disease. Int J Mol Sci 2016; 17(10): 1620.
[http://dx.doi.org/10.3390/ijms17101620] [PMID: 27669236]
[10]
Salvoza NC, Klinzing DC, Gopez-Cervantes J, Baclig MO. association of circulating serum miR-34a and miR-122 with dyslipidemia among patients with Non-alcoholic fatty liver disease. PLoS One 2016; 11(4): e0153497.
[http://dx.doi.org/10.1371/journal.pone.0153497] [PMID: 27077736]
[11]
Musa NI, Safwat E, Abdelhakam SM, Farid AM, Hetta WM. Noninvasive tool for the diagnosis of NAFLD in association with atherosclerotic cardiovascular risk. Egypt Liver J 2019; 9(1): 1.
[http://dx.doi.org/10.1186/s43066-019-0002-y]
[12]
Zhang YN, Fowler KJ, Hamilton G, et al. Liver fat imaging-a clinical overview of ultrasound, CT, and MR imaging. Br J Radiol 2018; 91(1089): 20170959.
[http://dx.doi.org/10.1259/bjr.20170959] [PMID: 29722568]
[13]
Papagianni M, Sofogianni A, Tziomalos K. Non-invasive methods for the diagnosis of nonalcoholic fatty liver disease. World J Hepatol 2015; 7(4): 638-48.
[http://dx.doi.org/10.4254/wjh.v7.i4.638] [PMID: 25866601]
[14]
Dongiovanni P, Meroni M, Longo M, Fargion S, Fracanzani A. miRNA signature in NAFLD: A turning point for a non-invasive diagnosis. Int J Mol Sci 2018; 19(12): 3966.
[http://dx.doi.org/10.3390/ijms19123966] [PMID: 30544653]
[15]
Hayes C, Chayama K. MicroRNAs as biomarkers for liver disease and hepatocellular carcinoma. Int J Mol Sci 2016; 17(3): 280.
[http://dx.doi.org/10.3390/ijms17030280] [PMID: 26927063]
[16]
Huang X, Yuan T, Tschannen M, et al. Characterization of human plasma-derived exosomal RNAs by deep sequencing. BMC Genomics 2013; 14(1): 319.
[http://dx.doi.org/10.1186/1471-2164-14-319] [PMID: 23663360]
[17]
Conde-Vancells J, Rodriguez-Suarez E, Embade N, et al. Characterization and comprehensive proteome profiling of exosomes secreted by hepatocytes. J Proteome Res 2008; 7(12): 5157-66.
[http://dx.doi.org/10.1021/pr8004887] [PMID: 19367702]
[18]
Taylor CJ, Satoor SN, Ranjan AK, Pereira e Cotta MV, Joglekar MV. A protocol for measurement of noncoding RNA in human serum. Exp Diabetes Res 2012; 2012: 1-4.
[http://dx.doi.org/10.1155/2012/168368] [PMID: 22811698]
[19]
Siddika T, Heinemann IU. Bringing MicroRNAs to Light: Methods for MicroRNA quantification and visualization in live cells. Front Bioeng Biotechnol 2021; 8: 619583.
[http://dx.doi.org/10.3389/fbioe.2020.619583] [PMID: 33537295]
[20]
Hou J, Lin L, Zhou W, Wang Z, Ding G, Dong Q, et al. Identification of miRNomes in human liver and HCC reveals miR-199a/b-3p as therapeutic target for Hepatocellular carcinoma. Cancer Cell 2011; 19(2): 232-43.
[http://dx.doi.org/10.1016/j.ccr.2011.01.001] [PMID: 21316602]
[21]
Gamazon ER, Innocenti F, Wei R, et al. A genome-wide integrative study of microRNAs in human liver. BMC Genomics 2013; 14(1): 395.
[http://dx.doi.org/10.1186/1471-2164-14-395] [PMID: 23758991]
[22]
Jopling C. Liver-specific microRNA-122: Biogenesis and function. RNA Biol 2012; 9(2): 137-42.
[http://dx.doi.org/10.4161/rna.18827] [PMID: 22258222]
[23]
Sharma S, Eghbali M. Influence of sex differences on microRNA gene regulation in disease. Biol Sex Differ 2014; 5(1): 3.
[http://dx.doi.org/10.1186/2042-6410-5-3] [PMID: 24484532]
[24]
Roderburg C, Urban GW, Bettermann K, et al. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology 2011; 53(1): 209-18.
[http://dx.doi.org/10.1002/hep.23922] [PMID: 20890893]
[25]
Celikbilek M, Baskol M, Taheri S, et al. Circulating microRNAs in patients with non-alcoholic fatty liver disease. World J Hepatol 2014; 6(8): 613-20.
[http://dx.doi.org/10.4254/wjh.v6.i8.613] [PMID: 25232454]
[26]
Tan Y, Ge G, Pan T, Wen D, Gan J. A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease. PLoS One 2014; 9(8): e105192.
[http://dx.doi.org/10.1371/journal.pone.0105192] [PMID: 25141008]
[27]
Pirola CJ, Fernández Gianotti T, Castaño GO, et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut 2015; 64(5): 800-12.
[http://dx.doi.org/10.1136/gutjnl-2014-306996] [PMID: 24973316]
[28]
Jampoka K, Muangpaisarn P, Khongnomnan K, Treeprasertsuk S, Tangkijvanich P, Payungporn S. Serum miR-29a and miR-122 as potential biomarkers for Non-Alcoholic Fatty Liver Disease (NAFLD). MicroRNA 2018; 7(3): 215-22.
[http://dx.doi.org/10.2174/2211536607666180531093302] [PMID: 29848284]
[29]
Zhang Y, Cheng X, Lu Z, et al. Upregulation of miR-15b in NAFLD models and in the serum of patients with fatty liver disease. Diabetes Res Clin Pract 2013; 99(3): 327-34.
[http://dx.doi.org/10.1016/j.diabres.2012.11.025] [PMID: 23287814]
[30]
Wang L, Zhang N, Wang Z, Ai D, Cao Z, Pan H. Decreased MiR-155 level in the peripheral blood of non-alcoholic fatty liver disease patients may serve as a biomarker and may influence LXR activity. Cell Physiol Biochem 2016; 39(6): 2239-48.
[http://dx.doi.org/10.1159/000447917] [PMID: 27832630]
[31]
Ye D, Zhang T, Lou G, et al. Plasma miR-17, miR-20a, miR-20b and miR-122 as potential biomarkers for diagnosis of NAFLD in type 2 diabetes mellitus patients. Life Sci 2018; 208: 201-7.
[http://dx.doi.org/10.1016/j.lfs.2018.07.029] [PMID: 30030064]
[32]
Yu F, Wang X, Zhao H, Hao Y, Wang W. Decreased serum miR-1296 may serve as an early biomarker for the diagnosis of Non-Alcoholic Fatty Liver Disease. Clin Lab 2019; 65.
[http://dx.doi.org/10.7754/Clin.Lab.2019.190335]
[33]
Ando Y, Yamazaki M, Yamada H, et al. Association of circulating miR-20a, miR-27a, and miR-126 with non-alcoholic fatty liver disease in general population. Sci Rep 2019; 9(1): 18856.
[http://dx.doi.org/10.1038/s41598-019-55076-z] [PMID: 31827150]
[34]
Yamada H, Suzuki K, Ichino N, et al. Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. Clin Chim Acta 2013; 424: 99-103.
[http://dx.doi.org/10.1016/j.cca.2013.05.021] [PMID: 23727030]
[35]
Akuta N, Kawamura Y, Arase Y, et al. Circulating MicroRNA‐122 and fibrosis stage predict mortality of Japanese patients with histopathologically confirmed NAFLD. Hepatol Commun 2020; 4(1): 66-76.
[http://dx.doi.org/10.1002/hep4.1445] [PMID: 31909356]
[36]
Wen Y, Han J, Chen J, et al. Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma. Int J Cancer 2015; 137(7): 1679-90.
[http://dx.doi.org/10.1002/ijc.29544] [PMID: 25845839]
[37]
Niu LJ, Zhang YM, Huang T, Sun XF, Luo SX. Exosomal microRNA-155 as a biomarker for hepatic fibrosis diagnosis and progression. Ann Transl Med 2021; 9(2): 137-7.
[http://dx.doi.org/10.21037/atm-20-7787] [PMID: 33569439]
[38]
Zhu HT, Liu RB, Liang YY, et al. Serum microRNA profiles as diagnostic biomarkers for HBV-positive hepatocellular carcinoma. Liver Int 2017; 37(6): 888-96.
[http://dx.doi.org/10.1111/liv.13356] [PMID: 28061012]
[39]
Jin Y, Wong YS, Goh BKP, et al. Circulating microRNAs as potential diagnostic and prognostic biomarkers in Hepatocellular carcinoma. Sci Rep 2019; 9(1): 10464.
[http://dx.doi.org/10.1038/s41598-019-46872-8] [PMID: 31320713]
[40]
Zeng Z, Dong J, Li Y, et al. The expression level and diagnostic value of microRNA-22 in HCC patients. Artif Cells Nanomed Biotechnol 2020; 48(1): 683-6.
[http://dx.doi.org/10.1080/21691401.2019.1703723] [PMID: 32088997]
[41]
Long XR, Zhang YJ, Zhang MY, Chen K, Zheng XFS, Wang HY. Identification of an 88-microRNA signature in whole blood for diagnosis of hepatocellular carcinoma and other chronic liver diseases. Aging 2017; 9(6): 1565-84.
[http://dx.doi.org/10.18632/aging.101253] [PMID: 28657540]
[42]
Zhu S, Liu W. Association of serum miR-205 with liver cirrhosis and cancer and its diagnostic significance. Int J Clin Exp Med 2018; 11(11): 12375-80.
[43]
Mohammed MA, Omar NM, Mohammed SA, Amin AM. Serum MicroRNA-1246 as a potential biomarker for HCV-related early-stage Hepatocellular carcinoma. Int J Cancer Res 2019; 15(2): 47-57.
[http://dx.doi.org/10.3923/ijcr.2019.47.57]
[44]
Liu AM, Yao TJ, Wang W, et al. Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: A retrospective cohort study. BMJ Open 2012; 2(2): e000825.
[http://dx.doi.org/10.1136/bmjopen-2012-000825] [PMID: 22403344]
[45]
Chen Y, Chen J, Liu Y, Li S, Huang P. Plasma miR-15b-5p, miR-338-5p, and miR-764 as biomarkers for hepatocellular carcinoma. Med Sci Monit 2015; 21: 1864-71.
[http://dx.doi.org/10.12659/MSM.893082] [PMID: 26119771]
[46]
Lv Z, Tao Y, Cai X, Zhou X, Li Y. Cluster of specified microRNAs in tissues and serum as biomarkers for early diagnosis of hepatocellular carcinoma. Int J Clin Exp Pathol 2018; 11(2): 990-7.
[PMID: 31938193]
[47]
Li LM, Hu ZB, Zhou ZX, et al. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res 2010; 70(23): 9798-807.
[http://dx.doi.org/10.1158/0008-5472.CAN-10-1001] [PMID: 21098710]
[48]
Bhattacharya S, Steele R, Shrivastava S, Chakraborty S, Di Bisceglie AM, Ray RB. Serum miR-30e and miR-223 as novel noninvasive biomarkers for Hepatocellular carcinoma. Am J Pathol 2016; 186(2): 242-7.
[http://dx.doi.org/10.1016/j.ajpath.2015.10.003] [PMID: 26776075]
[49]
Qi P, Cheng S, Wang H, Li N, Chen Y, Gao C. Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PLoS One 2011; 6(12): e28486.
[http://dx.doi.org/10.1371/journal.pone.0028486] [PMID: 22174818]
[50]
Zhou J, Yu L, Gao X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol 2011; 29(36): 4781-8.
[http://dx.doi.org/10.1200/JCO.2011.38.2697] [PMID: 22105822]
[51]
Ali HEA, Abdel Hameed R, Effat H, et al. Circulating microRNAs panel as a diagnostic tool for discrimination of HCV-associated hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2017; 41(4): e51-62.
[http://dx.doi.org/10.1016/j.clinre.2017.06.004] [PMID: 28750770]
[52]
Amr KS, Elmawgoud Atia HA, Elazeem Elbnhawy RA, Ezzat WM. Early diagnostic evaluation of miR-122 and miR-224 as biomarkers for hepatocellular carcinoma. Genes Dis 2017; 4(4): 215-21.
[http://dx.doi.org/10.1016/j.gendis.2017.10.003] [PMID: 30258925]
[53]
Luo J, Chen M, Huang H, et al. Circulating microRNA-122a as a diagnostic marker for hepatocellular carcinoma. OncoTargets Ther 2013; 6(April): 577-83.
[http://dx.doi.org/10.2147/OTT.S44215] [PMID: 23723713]
[54]
Tomimaru Y, Eguchi H, Nagano H, et al. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol 2012; 56(1): 167-75.
[http://dx.doi.org/10.1016/j.jhep.2011.04.026] [PMID: 21749846]
[55]
Zuo D, Chen L, Liu X, et al. Combination of miR-125b and miR-27a enhances sensitivity and specificity of AFP-based diagnosis of hepatocellular carcinoma. Tumour Biol 2016; 37(5): 6539-49.
[http://dx.doi.org/10.1007/s13277-015-4545-1] [PMID: 26637228]
[56]
Chen S, Chen H, Gao S, et al. Differential expression of plasma microRNA-125b in hepatitis B virus-related liver diseases and diagnostic potential for hepatitis B virus-induced hepatocellular carcinoma. Hepatol Res 2017; 47(4): 312-20.
[http://dx.doi.org/10.1111/hepr.12739] [PMID: 27152955]
[57]
Wang Y, Lee ATC, Ma JZI, et al. Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. J Biol Chem 2008; 283(19): 13205-15.
[http://dx.doi.org/10.1074/jbc.M707629200] [PMID: 18319255]
[58]
Zhuang L, Meng Z. Serum miR-224 reflects stage of hepatocellular carcinoma and predicts survival. BioMed Res Int 2015; 2015: 1-7.
[http://dx.doi.org/10.1155/2015/731781] [PMID: 25688365]
[59]
Tan Y, Ge G, Pan T, et al. A serum microRNA panel as potential biomarkers for hepatocellular carcinoma related with hepatitis B virus. PLoS One 2014; 9(9): e107986.
[http://dx.doi.org/10.1371/journal.pone.0107986] [PMID: 25238238]
[60]
Zekri ARN, Youssef ASED, El-Desouky ED, et al. Serum microRNA panels as potential biomarkers for early detection of hepatocellular carcinoma on top of HCV infection. Tumour Biol 2016; 37(9): 12273-86.
[http://dx.doi.org/10.1007/s13277-016-5097-8] [PMID: 27271989]
[61]
Zhu HT, Dong QZ, Sheng YY, et al. MicroRNA-29a-5p is a novel predictor for early recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection. PLoS One 2012; 7(12): e52393.
[http://dx.doi.org/10.1371/journal.pone.0052393] [PMID: 23285022]
[62]
Hou J, Lin L, Zhou W, et al. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 2011; 19(2): 232-43.
[http://dx.doi.org/10.1016/j.ccr.2011.01.001] [PMID: 21316602]
[63]
Wang F, Ying H, He B, Pan Y, Sun H, Wang S. Circulating miR-148/152 family as potential biomarkers in hepatocellular carcinoma. Tumour Biol 2016; 37(4): 4945-53.
[http://dx.doi.org/10.1007/s13277-015-4340-z] [PMID: 26531720]
[64]
Wang Y, Zhang C, Zhang P, et al. Serum exosomal microRNAs combined with alpha-fetoprotein as diagnostic markers of hepatocellular carcinoma. Cancer Med 2018; 7(5): 1670-9.
[http://dx.doi.org/10.1002/cam4.1390] [PMID: 29573235]
[65]
Han J, Li J, Qian Y, et al. Identification of plasma miR-148a as a noninvasive biomarker for hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2019; 43(5): 585-93.
[http://dx.doi.org/10.1016/j.clinre.2018.12.008] [PMID: 30824368]
[66]
Ning S, Liu H, Gao B, et al. miR-155, miR-96 and miR-99a as potential diagnostic and prognostic tools for the clinical management of hepatocellular carcinoma. Oncol Lett 2019; 18(3): 3381-7.
[http://dx.doi.org/10.3892/ol.2019.10606] [PMID: 31452818]
[67]
Li D, Liu X, Lin L, et al. MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. J Biol Chem 2011; 286(42): 36677-85.
[http://dx.doi.org/10.1074/jbc.M111.270561] [PMID: 21878637]
[68]
Shen J, Wang A, Wang Q, et al. Exploration of genome-wide circulating microRNA in hepatocellular carcinoma: MiR-483-5p as a potential biomarker. Cancer Epidemiol Biomarkers Prev 2013; 22(12): 2364-73.
[http://dx.doi.org/10.1158/1055-9965.EPI-13-0237] [PMID: 24127413]
[69]
Lin XJ, Chong Y, Guo ZW, et al. A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study. Lancet Oncol 2015; 16(7): 804-15.
[http://dx.doi.org/10.1016/S1470-2045(15)00048-0] [PMID: 26088272]
[70]
Zhang Y, Li T, Qiu Y, et al. Serum microRNA panel for early diagnosis of the onset of hepatocellular carcinoma. Medicine 2017; 96(2): e5642.
[http://dx.doi.org/10.1097/MD.0000000000005642] [PMID: 28079796]
[71]
Zhang Z, Meng H, Wang N, et al. Serum microRNA 143 and microRNA 215 as potential biomarkers for the diagnosis of chronic hepatitis and hepatocellular carcinoma. Diagn Pathol 2014; 9(1): 135.
[http://dx.doi.org/10.1186/1746-1596-9-135] [PMID: 24993656]
[72]
Chen L, Chu F, Cao Y, Shao J, Wang F. Serum miR-182 and miR-331-3p as diagnostic and prognostic markers in patients with hepatocellular carcinoma. Tumour Biol 2015; 36(10): 7439-47.
[http://dx.doi.org/10.1007/s13277-015-3430-2] [PMID: 25903466]
[73]
Shen X, Xue Y, Cong H, Wang X, Ju S. Dysregulation of serum microRNA-574-3p and its clinical significance in hepatocellular carcinoma. Ann Clin Biochem 2018; 55(4): 478-84.
[http://dx.doi.org/10.1177/0004563217741908] [PMID: 29065698]
[74]
Yu F, Lu Z, Chen B, Dong P, Zheng J. microRNA-150: a promising novel biomarker for hepatitis B virus-related hepatocellular carcinoma. Diagn Pathol 2015; 10(1): 129.
[http://dx.doi.org/10.1186/s13000-015-0369-y] [PMID: 26215970]
[75]
Shaheen NMH, Zayed N, Riad NM, et al. Role of circulating miR-182 and miR-150 as biomarkers for cirrhosis and hepatocellular carcinoma post HCV infection in Egyptian patients. Virus Res 2018; 255: 77-84.
[http://dx.doi.org/10.1016/j.virusres.2018.07.004] [PMID: 30003924]
[76]
Barshack I, Meiri E, Rosenwald S, et al. Differential diagnosis of hepatocellular carcinoma from metastatic tumors in the liver using microRNA expression. Int J Biochem Cell Biol 2010; 42(8): 1355-62.
[http://dx.doi.org/10.1016/j.biocel.2009.02.021] [PMID: 20619223]
[77]
Moshiri F, Salvi A, Gramantieri L, et al. Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma. Oncotarget 2018; 9(20): 15350-64.
[http://dx.doi.org/10.18632/oncotarget.24601] [PMID: 29632649]
[78]
Ali MA, Matboli M, El-Khazragy N, et al. Investigating miRNA-661 and ATG4-B mRNA expression as potential biomarkers for hepatocellular carcinoma. Biomarkers Med 2018; 12(3): 245-56.
[http://dx.doi.org/10.2217/bmm-2017-0273] [PMID: 29441798]
[79]
Chen X, Wang A. Clinical significance of miR-195 in hepatocellular carcinoma and its biological function in tumor progression. OncoTargets Ther 2019; 12: 527-34.
[http://dx.doi.org/10.2147/OTT.S190108] [PMID: 30666131]
[80]
El Mahdy HA, Abdelhamid IA, Amen AI, Abdelsameea E, Hassouna MM. MicroRNA-215 as a diagnostic marker in egyptian patients with hepatocellular carcinoma. Asian Pac J Cancer Prev 2019; 20(9): 2723-31.
[http://dx.doi.org/10.31557/APJCP.2019.20.9.2723] [PMID: 31554369]
[81]
Li L, Guo Z, Wang J, Mao Y, Gao Q. Serum miR-18a: A potential marker for hepatitis B virus-related hepatocellular carcinoma screening. Dig Dis Sci 2012; 57(11): 2910-6.
[http://dx.doi.org/10.1007/s10620-012-2317-y] [PMID: 22865399]
[82]
Ji J, Shi J, Budhu A, et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 2009; 361(15): 1437-47.
[http://dx.doi.org/10.1056/NEJMoa0901282] [PMID: 19812400]
[83]
Yang L, Xu Q, Xie H, Gu G, Jiang J. Expression of serum miR-218 in hepatocellular carcinoma and its prognostic significance. Clin Transl Oncol 2016; 18(8): 841-7.
[http://dx.doi.org/10.1007/s12094-015-1447-z] [PMID: 26586116]
[84]
Xie Y, Yao Q, Butt AM, et al. Expression profiling of serum microRNA-101 in HBV-associated chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Cancer Biol Ther 2014; 15(9): 1248-55.
[http://dx.doi.org/10.4161/cbt.29688] [PMID: 24971953]
[85]
Afonso M, Rodrigues P, Simão A, Castro R. Circulating microRNAs as potential biomarkers in non- alcoholic fatty liver disease and hepatocellular carcinoma. J Clin Med 2016; 5(3): 30.
[http://dx.doi.org/10.3390/jcm5030030] [PMID: 26950158]
[86]
Zhang JZ, Cai JJ, Yu Y, She ZG, Li H. Nonalcoholic fatty liver disease: An update on the diagnosis. Gene Expr 2019; 19(3): 187-98.
[http://dx.doi.org/10.3727/105221619X15553433838609] [PMID: 31010457]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy